Lowering of Circulating Sclerostin May Increase Risk of Atherosclerosis and Its Risk Factors: Evidence From a <scp>Genome‐Wide</scp> Association <scp>Meta‐Analysis</scp> Followed by Mendelian Randomization
In this study, we aimed to establish the causal effects of lowering sclerostin, target of the antiosteoporosis drug romosozumab, on atherosclerosis and its risk factors.
Saved in:
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
格式: | Revisão |
语言: | 英语 |
出版: |
2023
|
在线阅读: | https://doi.org/10.1002/art.42538 |
标签: |
添加标签
没有标签, 成为第一个标记此记录!
|